Boehringer Ingelheim strengthens early science portfolio through comprehensive multifaceted partnership with Peking University
Boehringer Ingelheim and Peking University (PKU) today announced an ambitious strategic partnership with the aim of jointly advancing early science innovation across a range of areas of high medical need.
The partnership will implement a multifaceted collaboration model that nimbly and flexibly caters for the specific needs of the involved research groups. It will comprise project based research, a joint post-doctorate fellowship program and a number of Boehringer Ingelheim endowed investigators. The partnership aims to strengthen Boehringer Ingelheim’s portfolio of early and unique pipeline projects supporting the company’s aspiration to be at the forefront of science and technology and deliver more first in class medicines with breakthrough potential. It takes Boehringer Ingelheim’s research and development efforts in Asia to the next level.
Research teams at PKU will work closely with their counterparts at Boehringer Ingelheim to leverage the company’s expertise in pharmaceutical research and development with their novel approaches and insights to identify novel targets and medicines within and beyond the company’s key therapeutic areas. These include cancer, cancer immunology and immune modulation, respiratory, cardiometabolic and central nervous system diseases.
“We are excited to launch a comprehensive partnership program with scientists from PKU who are at the forefront of biomedical discovery. This collaboration with one of the most prestigious scientific institutions will enable us to benefit from and contribute to the impressive boom in life science research in China,” said Clive R. Wood, Ph.D., Senior Corporate Vice President, Discovery Research, Boehringer Ingelheim. “The flexible partnership model developed allows PKU and Boehringer Ingelheim scientists to work hand in hand to jointly advance promising biomedical discoveries.”
Asia, and in particular China, has gained a reputation as a leading center of excellence in biomedical research, opening new collaborative opportunities for Boehringer Ingelheim to provide the next wave of medical innovation. The PKU collaboration continues the success of recent projects in China, such as the China Southeast University Institute of Life Sciences’ project with Boehringer Ingelheim to develop new treatment approaches for hearing loss through regeneration of hair cells.
“This new collaboration with Boehringer Ingelheim reflects a mutual goal for excellence and providing innovative approaches that bridge the gap between basic science and medical development,” said Jie Wang, Vice President, Peking University, China. “We are proud to work with Boehringer Ingelheim to advance knowledge that will benefit patients in China and worldwide.”
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
Please click on the link below for ‘Notes to Editors’ and ‘References’:
Media + PR
Phone: +49 6132 – 77 90815
Fax: +49 6132 – 77 6601
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Ved at skrive dig op her, vil du modtage pressemeddelelser på mail når de udsendes. Indtast din mail og følg instruktionerne. Det er ligeså let at melde sig fra igen.
Flere pressemeddelelser fra Business Wire
EXCLUSIVE-GROUP19.10.2017 10:02 | pressemeddelelse
Exclusive Group Adds Mellanox to BigTec Portfolio
DUCO19.10.2017 09:03 | pressemeddelelse
More Firms Select Duco for Mandatory MiFID II Reconciliation
SIAE-MICROELETTRONICA19.10.2017 09:02 | pressemeddelelse
SIAE MICROELETTRONICA Successfully Tests The SDN Application iVeritas in Telefónica Deutschland’s SDN Live Wireless Network
NV-RIMINI-STREET,-INC.19.10.2017 00:02 | pressemeddelelse
Rimini Street Expands Investment and Operations in Europe
CA-GILEAD-SCIENCES18.10.2017 23:45 | pressemeddelelse
Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy
NY-IFF18.10.2017 22:18 | pressemeddelelse
IFF Launches Re-Imagine…™ Programs to Tap Unmet Consumer Opportunities, Speed Innovation
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum